Specify a stock or a cryptocurrency in the search bar to get a summary
Enliven Therapeutics Inc.
ELVNEnliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado. Address: 6200 Lookout Road, Boulder, CO, United States, 80301
Analytics
WallStreet Target Price
35.67 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ELVN
Dividend Analytics ELVN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ELVN
Stock Valuation ELVN
Financials ELVN
Results | 2019 | Dynamics |